메폴리주맙 시장 보고서(2026년)

Mepolizumab is a humanized monoclonal antibody that specifically binds to and blocks interleukin-5, a signaling molecule that controls the development, activation, and lifespan of eosinophils, thereby lowering eosinophil-driven inflammation and regulating immune responses in conditions associated with high eosinophil counts. It is mainly prescribed for the treatment of severe eosinophilic asthma and other eosinophil-related disorders, where it assists in reducing flare-ups, enhancing symptom management, and decreasing reliance on systemic corticosteroids.

The primary indications of mepolizumab include severe asthma, eosinophilic granulomatosis with polyangiitis, chronic obstructive pulmonary disease, and other eosinophilic disorders. Severe asthma refers to a condition characterized by persistent symptoms and frequent exacerbations despite high-intensity treatment. These indications apply across age groups including children aged 6 to 11 years, adolescents aged 12 to 17 years, and adults aged 18 years and older. Distribution occurs through direct sales, retail pharmacy, and online pharmacy channels, while end users include hospitals, clinics, and home care settings.

Tariffs are impacting the mepolizumab market by increasing the expenses of biologic raw materials, production equipment, and cold chain logistics, thereby raising overall treatment costs. Indications such as severe asthma and eosinophilic granulomatosis with polyangiitis are particularly affected, along with distribution channels like retail and online pharmacies that rely on imported biologics. Regions dependent on pharmaceutical imports, especially emerging markets, are facing supply chain disruptions and pricing pressure. Nevertheless, tariffs are also encouraging the development of local biologics manufacturing and investment in domestic production capacity, which may enhance long-term supply stability and reduce dependence on imports.

The mepolizumab market research report is one of a series of new reports from The Business Research Company that provides mepolizumab market statistics, including mepolizumab industry global market size, regional shares, competitors with a mepolizumab market share, detailed mepolizumab market segments, market trends and opportunities, and any further data you may need to thrive in the mepolizumab industry. This mepolizumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mepolizumab market size has grown strongly in recent years. It will grow from $2.22 billion in 2025 to $2.38 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to rising prevalence of severe asthma, increasing awareness of eosinophilic disorders, growth in biologics research and development, expansion of specialty care services, improved diagnostic capabilities for inflammatory diseases.

The mepolizumab market size is expected to see strong growth in the next few years. It will grow to $3.21 billion by 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, expansion of biologics pipeline, growing demand for home-based treatment options, advancements in targeted immunotherapies, rising healthcare investments in chronic disease management. Major trends in the forecast period include increasing adoption of monoclonal antibody therapies, growing use of biologics for severe asthma management, rising demand for steroid-sparing treatment options, expanding clinical applications in eosinophilic disorders, improved patient adherence through targeted therapies.

The increasing global burden of asthma is anticipated to propel the growth of the mepolizumab market coming years. The increasing global burden of asthma is anticipated to propel the growth of the mepolizumab market coming years. Asthma refers to a chronic respiratory condition in which the airways (bronchi) become inflamed, narrow, and produce excess mucus, making it difficult to breathe. The rise of asthma is due to people being exposed to a combination of genetic and environmental factors, which can trigger inflammation in the airways of the body and make the lungs more sensitive, which leads to a higher prevalence of asthma. Mepolizumab helps asthma by allowing the reduction of inflammation caused by eosinophils, which are a type of white blood cell that contributes to airway swelling and asthma attacks. For instance, in February 2026, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based independent statutory agency, asthma contributes 2.5% to Australia's total disease burden in 2024, is the leading cause of disease burden among children aged 1-9, drives approximately $1.3 billion in healthcare spending in 2023-24, and shows higher prevalence and hospitalization rates in boys compared to girls. Furthermore, in February 2023, according to NHS England, a UK-based executive non-departmental public body, approximately 5.4 million individuals are undergoing asthma treatment, with around 160,000 new diagnoses occurring annually, and occupational exposure contributing to nearly 9-15% of adult-onset asthma cases. Therefore, the increasing global burden of asthma is driving the growth of the mepolizumab market.

Leading companies operating in the mepolizumab market are focusing on developing innovative products, such as eosinophil-targeting biologics to expand therapeutic indications and improve disease management outcomes. An eosinophil-targeting biologic is a monoclonal antibody therapy that inhibits interleukin-5 to reduce eosinophil-mediated inflammation. For example, in January 2026, GlaxoSmithKline PLC, a UK-based biopharmaceutical company, announced China's National Medical Products Administration (NMPA) approval of Nucala (mepolizumab). The therapy demonstrates statistically significant reductions in moderate to severe exacerbations in patients with eosinophilic chronic obstructive pulmonary disease when added to standard inhaled treatments. Its approval introduces a targeted biologic option in a large patient population, supporting improved clinical outcomes and reducing hospitalization burden.

The growing adoption of biologic treatments is anticipated to drive the growth of the mepolizumab market coming years. The growing adoption of biologic treatments is anticipated to drive the growth of the mepolizumab market coming years. Biologic treatments are advanced therapeutic agents derived from living organisms or their components, designed to target specific molecular pathways involved in disease pathogenesis, particularly in immune-mediated and inflammatory conditions. A key factor driving the growing adoption of biologic treatments is their ability to deliver highly targeted mechanisms of action, which enables improved clinical outcomes with reduced off-target effects compared to conventional therapies, thereby increasing physician confidence and patient preference for precision-based interventions. Mepolizumab selectively inhibits interleukin-5, demonstrating the clinical value of biologic treatments in effectively managing eosinophilic conditions and reinforcing their adoption in respiratory care. For instance, in August 2023, according to the British Generic Manufacturers Association, a UK-based trade association, forecasts from the Office of Health Economics indicate that National Health Service biosimilar sales are expected to reach approximately $33 billion (£26 billion) over the period from 2023 to 2028. Therefore, the growing adoption of biologic treatments is driving the growth of the mepolizumab market.

Major companies operating in the mepolizumab market are GlaxoSmithKline plc, Bio-Thera Solutions Ltd.

North America was the dominating region in the mepolizumab market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the mepolizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the mepolizumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mepolizumab market consists of sales of products such as lyophilized powder for reconstitution into a subcutaneous injection, a prefilled syringe for subcutaneous administration, and a single-use autoinjector designed for subcutaneous delivery. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mepolizumab Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses mepolizumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mepolizumab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mepolizumab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Indication: Severe Asthma; Eosinophilic Granulomatosis With Polyangiitis; Chronic Obstructive Pulmonary Disease; Other Eosinophilic Disorders
• 2) By Age Group: Children 6 To 11 Years; Adolescents 12 To 17 Years; Adults 18 Years And Older
• 3) By Distribution Channel: Direct Sales; Retail Pharmacy; Online Pharmacy
• 4) By End User: Hospitals; Clinics; Home Care Settings
• Subsegments:
• 1) By Severe Asthma: Allergic Severe Asthma; Non Allergic Severe Asthma; Late Onset Severe Asthma
• 2) By Eosinophilic Granulomatosis With Polyangiitis: Active Eosinophilic Granulomatosis With Polyangiitis; Relapsing Eosinophilic Granulomatosis With Polyangiitis; Remission Phase Eosinophilic Granulomatosis With Polyangiitis
• 3) By Chronic Obstructive Pulmonary Disease: Chronic Bronchitis Dominant Chronic Obstructive Pulmonary Disease; Emphysema Dominant Chronic Obstructive Pulmonary Disease; Frequent Exacerbator Chronic Obstructive Pulmonary Disease
• 4) By Other Eosinophilic Disorders: Hypereosinophilic Syndrome; Eosinophilic Esophagitis; Eosinophilic Chronic Rhinosinusitis
• Companies Mentioned: GlaxoSmithKline plc; Bio-Thera Solutions Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Mepolizumab Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Mepolizumab Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Mepolizumab Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Mepolizumab Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Monoclonal Antibody Therapies
  • 4.2.2 Growing Use Of Biologics For Severe Asthma Management
  • 4.2.3 Rising Demand For Steroid-Sparing Treatment Options
  • 4.2.4 Expanding Clinical Applications In Eosinophilic Disorders
  • 4.2.5 Improved Patient Adherence Through Targeted Therapies

5. Mepolizumab Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Home Care Settings
• 5.4 Specialty Respiratory Centers
• 5.5 Other End Users

6. Mepolizumab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Mepolizumab Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Mepolizumab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Mepolizumab Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Mepolizumab Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Mepolizumab Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Mepolizumab Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Mepolizumab Market Segmentation

• 9.1. Global Mepolizumab Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Severe Asthma, Eosinophilic Granulomatosis With Polyangiitis, Chronic Obstructive Pulmonary Disease, Other Eosinophilic Disorders
• 9.2. Global Mepolizumab Market, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Children 6 To 11 Years, Adolescents 12 To 17 Years, Adults 18 Years And Older
• 9.3. Global Mepolizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Direct Sales, Retail Pharmacy, Online Pharmacy
• 9.4. Global Mepolizumab Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Home Care Settings
• 9.5. Global Mepolizumab Market, Sub-Segmentation Of Severe Asthma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Allergic Severe Asthma, Non Allergic Severe Asthma, Late Onset Severe Asthma
• 9.6. Global Mepolizumab Market, Sub-Segmentation Of Eosinophilic Granulomatosis With Polyangiitis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Active Eosinophilic Granulomatosis With Polyangiitis, Relapsing Eosinophilic Granulomatosis With Polyangiitis, Remission Phase Eosinophilic Granulomatosis With Polyangiitis
• 9.7. Global Mepolizumab Market, Sub-Segmentation Of Chronic Obstructive Pulmonary Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chronic Bronchitis Dominant Chronic Obstructive Pulmonary Disease, Emphysema Dominant Chronic Obstructive Pulmonary Disease, Frequent Exacerbator Chronic Obstructive Pulmonary Disease
• 9.8. Global Mepolizumab Market, Sub-Segmentation Of Other Eosinophilic Disorders, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hypereosinophilic Syndrome, Eosinophilic Esophagitis, Eosinophilic Chronic Rhinosinusitis

10. Mepolizumab Market Regional And Country Analysis

• 10.1. Global Mepolizumab Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Mepolizumab Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Mepolizumab Market

• 11.1. Asia-Pacific Mepolizumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Mepolizumab Market

• 12.1. China Mepolizumab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Mepolizumab Market

• 13.1. India Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Mepolizumab Market

• 14.1. Japan Mepolizumab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Mepolizumab Market

• 15.1. Australia Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Mepolizumab Market

• 16.1. Indonesia Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Mepolizumab Market

• 17.1. South Korea Mepolizumab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Mepolizumab Market

• 18.1. Taiwan Mepolizumab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Mepolizumab Market

• 19.1. South East Asia Mepolizumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Mepolizumab Market

• 20.1. Western Europe Mepolizumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Mepolizumab Market

• 21.1. UK Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Mepolizumab Market

• 22.1. Germany Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Mepolizumab Market

• 23.1. France Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Mepolizumab Market

• 24.1. Italy Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Mepolizumab Market

• 25.1. Spain Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Mepolizumab Market

• 26.1. Eastern Europe Mepolizumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Mepolizumab Market

• 27.1. Russia Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Mepolizumab Market

• 28.1. North America Mepolizumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Mepolizumab Market

• 29.1. USA Mepolizumab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Mepolizumab Market

• 30.1. Canada Mepolizumab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Mepolizumab Market

• 31.1. South America Mepolizumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Mepolizumab Market

• 32.1. Brazil Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Mepolizumab Market

• 33.1. Middle East Mepolizumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Mepolizumab Market

• 34.1. Africa Mepolizumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Mepolizumab Market, Segmentation By Indication, Segmentation By Age Group, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Mepolizumab Market Regulatory and Investment Landscape

36. Mepolizumab Market Competitive Landscape And Company Profiles

• 36.1. Mepolizumab Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Mepolizumab Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Mepolizumab Market Company Profiles
  • 36.3.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Bio-Thera Solutions Ltd Overview, Products and Services, Strategy and Financial Analysis

37. Global Mepolizumab Market Competitive Benchmarking And Dashboard

38. Upcoming Startups in the Market

39. Key Mergers And Acquisitions In The Mepolizumab Market

40. Mepolizumab Market High Potential Countries, Segments and Strategies

• 40.1 Mepolizumab Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Mepolizumab Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Mepolizumab Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer